NovaBridge Biosciences (NBP) Liabilities and Shareholders Equity (2018 - 2022)
NovaBridge Biosciences (NBP) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $572.8 million as the latest value for Q4 2022.
- Quarterly Liabilities and Shareholders Equity fell 34.62% to $572.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.7 billion through Dec 2022, up 9.46% year-over-year, with the annual reading at $572.8 million for FY2022, 34.62% down from the prior year.
- Liabilities and Shareholders Equity for Q4 2022 was $572.8 million at NovaBridge Biosciences, down from $876.1 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $955.7 million in Q4 2020, with the low at $246.5 million in Q4 2019.
- Average Liabilities and Shareholders Equity over 5 years is $598.9 million, with a median of $572.8 million recorded in 2022.
- The sharpest move saw Liabilities and Shareholders Equity skyrocketed 287.67% in 2020, then crashed 34.62% in 2022.
- Over 5 years, Liabilities and Shareholders Equity stood at $343.6 million in 2018, then decreased by 28.26% to $246.5 million in 2019, then surged by 287.67% to $955.7 million in 2020, then decreased by 8.33% to $876.1 million in 2021, then plummeted by 34.62% to $572.8 million in 2022.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $572.8 million, $876.1 million, and $955.7 million for Q4 2022, Q4 2021, and Q4 2020 respectively.